Loading clinical trials...
Loading clinical trials...
Immunological Efficacy of a Prime-Boost Strategy Combining a 7-Valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-Valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-Infected Adults. ANRS 114 PNEUMOVAC.
Conditions
Interventions
7-valent pneumococcal conjugate vaccine (vaccine)
23-valent pneumococcal conjugate vaccine (vaccine)
Start Date
February 1, 2003
Completion Date
January 1, 2006
Last Updated
March 21, 2008
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT05897099
NCT06665646
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions